Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial

JAMA

Volumn 284, Issue 17, 2000, Pages 2215-2221

  Apfel, Stuart C ^a   Schwartz, Sherwin ^b   Adornato, Bruce T ^c   Freeman, Roy ^d   Biton, Victor ^e   Rendell, Marc ^f   Vinik, Aaron ^g   Giuliani, Michael ^h   Stevens, J Clarke ⁱ   Barbano, Richard ^j   Dyck, Peter J ^k  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Diabetes and Glandular Disease Clinic   (United States)

^c Beth Israel Deaconess Medical Center ^*

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e Arkansas AHEC Program   (United States)

^f CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

ⁱ MAYO CLINIC   (United States)

^j UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^k MAYO CLINIC COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT NERVE GROWTH FACTOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERALGESIA; MAJOR CLINICAL STUDY; MALE; MYALGIA; NERVE CONDUCTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034328085     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.284.17.2215     Document Type: Article

References (26)

1. The synthesis of nerve growth factor (NGF) in developing skin is independent of innervation
2. Retrograde axonal transport of transmitter enzymes, fucose labeled protein and nerve growth factor in streptozocin-diabetic rats
3. Retrograde axonal transport of 251 nerve growth factor in ileal mesenteric nerves in vitro
4. Axonal transport of endogenous nerve growth factor (NGF) and NGF receptor in experimental diabetic neuropathy
5. Deficits in sciatic nerve neuropeptide content coincide with a reduction in target tissue nerve growth factor messenger RNA in streptozocin-diabetic rat
6. The role of endogenous nerve growth factor in human diabetic neuropathy
7. Nerve growth factor prevents toxic neuropathy in mice
8. Nerve growth factor prevents experimental cisplatin neuropathy
9. Nerve growth factor administration protects against experimental diabetic sensory neuropathy
10. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy
11. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection
12. Variables influencing neuropathic endpoints
13. Vibratory and cooling detection thresholds compared with other tests in diagnosing and staging diabetic neuropathy
14. Cool, warm and heat-pain detection thresholds
15. Quantitative sensory testing: Methodology, applications, and future directions
16. A 4, 2, and 1 stepping algorithm for quick and accurate estimation of cutaneous sensation threshold
17. A standard test of heat pain response using CASE IV
18. Diabetic polyneuropathy in controlled clinical trials
19. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort
20. A nerve growth stimulating factor isolated from sarcomas 37 and 180
21. Nerve growth factor stimulates the development of substance P in sensory ganglia
22. Differential regulation of calcitonin gene related peptide and substance P in cultured neonatal rat vagal sensory neurons
23. Endogenous NGF and nerve impulses regulate the collateral sprouting of sensory axons in the skin of the adult rat
24. Role of nerve growth factor in oxidant-antioxidant balance and neuronal injury
25. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects